Premium
Ergot Derivatives for Parkinsonism
Author(s) -
Calne Donald B.,
Williams Adrian C.,
Nutt John G.,
Neophytides Andreas,
Eisler Toomas,
Teychenne Paul F.
Publication year - 1978
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.1978.tb77384.x
Subject(s) - bromocriptine , parkinsonism , levodopa , dyskinesia , medicine , agonist , dopaminergic , pharmacology , dopamine agonist , antagonist , anesthesia , dopamine , parkinson's disease , disease , hormone , prolactin , receptor
The response of Parkinsonism to three ergot derivatives which modify dopaminergic transmission was studied. cf 25‐397 behaved more as an antagonist than an agonist. Lergotrile was an agonist with therapeutic properties marred by prominent hepatotoxicity. Bromocriptine is an effective anti–Parkinsonian agent, particularly useful in patients with prominent dyskinesia or “on–off” reactions to levodopa; in most patients optimal results have been obtained by combining from 40 to 90 mg of bromocriptine daily with approximately 60% of the previous maximal dose of levodopa. Unfortunately, only some 50% of patients tolerate long–term bromocriptine therapy, but all adverse reactions have been dose dependent and reversible.